Abstract:BACKGROUND: Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca 2+ /calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders. METHODS: To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ. We generated mice harboring a phospho-resistant CaMKIIδ mutation in the germline and subjected these mice to severe transverse aortic constriction, a model for heart failure. Cardiac function, transcriptional changes, apoptosis, and fibrosis were assessed by echocardiography, RNA sequencing, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and standard histology, respectively. Specificity toward CaMKIIδ gene editing was assessed using deep amplicon sequencing. Cellular Ca 2+ homeostasis was analyzed using epifluorescence microscopy in Fura-2–loaded cardiomyocytes. RESULTS: Within 2 weeks after severe transverse aortic constriction surgery, 65% of all wild-type mice died, and the surviving mice showed a dramatically impaired cardiac function. In contrast to wild-type mice, CaMKIIδ phospho-resistant gene-edited mice showed a mortality rate of only 11% and exhibited a substantially improved cardiac function after severe transverse aortic constriction. Moreover, CaMKIIδ phospho-resistant mice were protected from heart failure–related aberrant changes in cardiac gene expression, myocardial apoptosis, and subsequent fibrosis, which were observed in wild-type mice after severe transverse aortic constriction. On the basis of identical mouse and human genome sequences encoding the autophosphorylation site of CaMKIIδ , we deployed the same editing strategy to modify this pathogenic site in human induced pluripotent stem cells. It is notable that we detected a >2000-fold increased specificity for editing of CaMKIIδ compared with other CaMKII isoforms, which is an important safety feature. Although wild-type cardiomyocytes showed impaired Ca 2+ transients and an increased frequency of arrhythmias after chronic β-adrenergic stress, CaMKIIδ -edited cardiomyocytes were protected from these adverse responses. CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.

Abstract 16920: Permanent Reduction of Ryr2 Improves Lv Ejection Fraction in Heart Failure

Enhanced Basal Activity of a Cardiac Ca2+ Release Channel (ryanodine Receptor) Mutant Associated with Ventricular Tachycardia and Sudden Death.

Targeting RyR2 with a Phosphorylation Site-Specific Nanobody Reverses Dysfunction of Failing Cardiomyocytes in Rat

Targeting Ryr2 With A Phosphorylation Site-Specific Nanobody Reverses Dysfunction Of Failing Cardiomyocytes In Rats

Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia

Abstract 3768: the Deficiency of Ryanodine Receptor Type 2 Accelerates Transition from Adaptive Cardiac Hypertrophy to Dysfunction During Pressure Overload

Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice

RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure

Cardiac RNase Z edited via CRISPR-Cas9 drives heart hypertrophy in Drosophila

Preserved cardiac performance and adrenergic response in a rabbit model with decreased ryanodine receptor 2 expression

Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice

Attempts to Create Transgenic Mice Carrying the Q3924E Mutation in RyR2 Ca2+ Binding Site

Increased Ca2+ Transient Underlies RyR2-Related Left Ventricular Noncompaction

Cardiac Hypertrophy and Arrhythmia in Mice Induced by a Mutation in Ryanodine Receptor 2

Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation

Novel Ryanodine Receptor Mutation Associated With Hypertrophic Cardiomyopathy Induces Cardiac Remodeling and Arrhythmia in Mice

Ryanodine Receptor Stabilization Therapy Suppresses Ca 2+ -Based Arrhythmias in a Novel Model of Metabolic HFpEF

Gene Therapy with the N-Terminus of Junctophilin-2 Improves Heart Failure in Mice

RyR2 Stabilizer Attenuates Cardiac Hypertrophy by Downregulating TNF-α/NF-κB/NLRP3 Signaling Pathway through Inhibiting Calcineurin

Ablation of CaMKIIδ Oxidation by CRISPR-Cas9 Base Editing As a Therapy for Cardiac Disease

Ryanodine Receptor Stabilization Therapy Suppresses Ca -Based Arrhythmias in a Novel Model of Metabolic HFpEF